Cargando…

Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill

INTRODUCTION: Hyperlactatemia is frequent in critically ill patients and is often used as a marker of adverse outcome. However, studies to date have focused on selected intensive care unit (ICU) populations. We sought to determine the occurrence and relation of hyperlactatemia with ICU mortality in...

Descripción completa

Detalles Bibliográficos
Autores principales: Khosravani, Houman, Shahpori, Reza, Stelfox, H Thomas, Kirkpatrick, Andrew W, Laupland, Kevin B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717461/
https://www.ncbi.nlm.nih.gov/pubmed/19523194
http://dx.doi.org/10.1186/cc7918
_version_ 1782169904025174016
author Khosravani, Houman
Shahpori, Reza
Stelfox, H Thomas
Kirkpatrick, Andrew W
Laupland, Kevin B
author_facet Khosravani, Houman
Shahpori, Reza
Stelfox, H Thomas
Kirkpatrick, Andrew W
Laupland, Kevin B
author_sort Khosravani, Houman
collection PubMed
description INTRODUCTION: Hyperlactatemia is frequent in critically ill patients and is often used as a marker of adverse outcome. However, studies to date have focused on selected intensive care unit (ICU) populations. We sought to determine the occurrence and relation of hyperlactatemia with ICU mortality in all patients admitted to four ICUs in a large regional critical care system. METHODS: All adults ([greater than or equal to] 18 years) admitted to ICUs in the Calgary Health Region (population 1.2 million) during 2003 to 2006 were included retrospectively. Lactate determinations were at the discretion of the attending service and hyperlactatemia was defined by a lactate level > 2 mmol/L. RESULTS: A total of 13,932 ICU admissions occurred among 11,581 patients. The median age was 63 years (37% female), the mean APACHE II score was 25 ± 9 (n = 13,922). At presentation (within first day of admission), 12,246 patients had at least one lactate determination and the median peak lactate was 1.8 (IQR 1.2 to 2.9) mmol/L. The cumulative incidence of at least one documented episode of hyperlactatemia was 5578/13,932 (40%); 5058 (36%) patients had hyperlactatemia at presentation, and a further 520 (4%) developed hyperlactatemia subsequently. The incidence of hyperlactatemia varied significantly by major admitting diagnostic category (P < 0.001) and was highest among neuro/trauma patients 1053/2328 (45%), followed by medical 2047/4935 (41%), other surgical 900/2274 (40%), and cardiac surgical 1578/4395 (36%). Among a cohort of 9107 first admissions with ICU stay of at least one day, both hyperlactatemia at presentation (712/3634 (20%) vs. 289/5473 (5%); P < 0.001) and its later development (101/379 (27%) vs. 188/5094 (4%); P < 0.001) were associated with significantly increased case fatality rates as compared with patients without elevated lactate. After controlling for confounding effects in multivariable logistic regression analysis, hyperlactatemia was an independent risk factor for death. CONCLUSIONS: Hyperlactatemia is common among the critically ill and predicts risk for death.
format Text
id pubmed-2717461
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27174612009-07-29 Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill Khosravani, Houman Shahpori, Reza Stelfox, H Thomas Kirkpatrick, Andrew W Laupland, Kevin B Crit Care Research INTRODUCTION: Hyperlactatemia is frequent in critically ill patients and is often used as a marker of adverse outcome. However, studies to date have focused on selected intensive care unit (ICU) populations. We sought to determine the occurrence and relation of hyperlactatemia with ICU mortality in all patients admitted to four ICUs in a large regional critical care system. METHODS: All adults ([greater than or equal to] 18 years) admitted to ICUs in the Calgary Health Region (population 1.2 million) during 2003 to 2006 were included retrospectively. Lactate determinations were at the discretion of the attending service and hyperlactatemia was defined by a lactate level > 2 mmol/L. RESULTS: A total of 13,932 ICU admissions occurred among 11,581 patients. The median age was 63 years (37% female), the mean APACHE II score was 25 ± 9 (n = 13,922). At presentation (within first day of admission), 12,246 patients had at least one lactate determination and the median peak lactate was 1.8 (IQR 1.2 to 2.9) mmol/L. The cumulative incidence of at least one documented episode of hyperlactatemia was 5578/13,932 (40%); 5058 (36%) patients had hyperlactatemia at presentation, and a further 520 (4%) developed hyperlactatemia subsequently. The incidence of hyperlactatemia varied significantly by major admitting diagnostic category (P < 0.001) and was highest among neuro/trauma patients 1053/2328 (45%), followed by medical 2047/4935 (41%), other surgical 900/2274 (40%), and cardiac surgical 1578/4395 (36%). Among a cohort of 9107 first admissions with ICU stay of at least one day, both hyperlactatemia at presentation (712/3634 (20%) vs. 289/5473 (5%); P < 0.001) and its later development (101/379 (27%) vs. 188/5094 (4%); P < 0.001) were associated with significantly increased case fatality rates as compared with patients without elevated lactate. After controlling for confounding effects in multivariable logistic regression analysis, hyperlactatemia was an independent risk factor for death. CONCLUSIONS: Hyperlactatemia is common among the critically ill and predicts risk for death. BioMed Central 2009 2009-06-12 /pmc/articles/PMC2717461/ /pubmed/19523194 http://dx.doi.org/10.1186/cc7918 Text en Copyright © 2009 Khosravani et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Khosravani, Houman
Shahpori, Reza
Stelfox, H Thomas
Kirkpatrick, Andrew W
Laupland, Kevin B
Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill
title Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill
title_full Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill
title_fullStr Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill
title_full_unstemmed Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill
title_short Occurrence and adverse effect on outcome of hyperlactatemia in the critically ill
title_sort occurrence and adverse effect on outcome of hyperlactatemia in the critically ill
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2717461/
https://www.ncbi.nlm.nih.gov/pubmed/19523194
http://dx.doi.org/10.1186/cc7918
work_keys_str_mv AT khosravanihouman occurrenceandadverseeffectonoutcomeofhyperlactatemiainthecriticallyill
AT shahporireza occurrenceandadverseeffectonoutcomeofhyperlactatemiainthecriticallyill
AT stelfoxhthomas occurrenceandadverseeffectonoutcomeofhyperlactatemiainthecriticallyill
AT kirkpatrickandreww occurrenceandadverseeffectonoutcomeofhyperlactatemiainthecriticallyill
AT lauplandkevinb occurrenceandadverseeffectonoutcomeofhyperlactatemiainthecriticallyill